Metamark Genetics, Inc. Appoints Tyler Aldredge As Senior Vice President Of Clinical Laboratory Operations
Leadership role projected to further enhance Company’s clinical operational excellence
November 2, 2015
CAMBRIDGE, Mass. -- Metamark Genetics, Inc., (“Metamark” or the “Company”), a leader in commercializing high-value urologic oncology products, announced that Tyler Aldredge joined Metamark’s executive team as senior vice president of clinical laboratory operations, effective October 26, 2015.
“Tyler brings an impressive breadth of leadership experience in clinical and laboratory operations,” said Kenneth Weg, Metamark President and CEO. “We’re very excited to have someone with Tyler’s respectable background, proven management expertise, and passion for innovation in cutting-edge laboratory R&D join our team. With Tyler on board, Metamark is well-poised to serve the comprehensive diagnostic and prognostic needs of the urological clinical community with advanced testing products, including our lead product, ProMark®, which continues to make giant strides in providing better information to aid in prostate cancer treatment decisions.”
Tyler Aldredge joins the Metamark team with a wealth of leadership, operations management, and operational quality experience in both clinical and research laboratories, while bringing extensive proficiency in process development and laboratory automation. Most recently, Tyler held the position of senior director of laboratory operations at Good Start Genetics, where he directed the clinical laboratory that performs molecular genetic testing for carrier screening and pre-implantation screening. Previously, Tyler held the role of vice president of laboratory operations at Expression Analysis where he led laboratory operations for the genomic services business that provided next-gen sequencing (NGS) and microarray-based genotyping and gene expression services. Tyler has held executive and leadership positions at Quintiles Transnational, Genzyme Genetics, The Broad Institute, Harvard University's Bauer Center for Genomic Research, and Codon Devices. In the early part of his career, Tyler built high-throughput automated DNA sequencing systems for Sanofi and Genome Therapeutics, which ultimately contributed to the Human Genome Project.
Tyler received a B.S. in Bioengineering from Syracuse University and a master’s in Biomedical Engineering from the Worcester Polytechnic Institute.
About ProMark®
Launched in late 2014, ProMark® is the first proteomic classifier of biopsied prostate tissue to assess whether an early-stage prostate tumor is aggressive or indolent. Test results generated in Metamark’s Cambridge, Mass. CLIA-certified laboratory can aid the decision to treat the cancer aggressively or to choose a course of active surveillance.
About Metamark®
Metamark Genetics, Inc. is a privately-held biotechnology company founded to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care. The company’s proprietary genomic and proteomic discovery platforms have led to significant discoveries in several disease areas, including prostate, bladder, colon, and breast cancers. Through the acquisition of HealthTronics Laboratory Solutions in 2013, Metamark has become a leading provider of specialty urological pathology testing services with the first fully integrated clinical model for the prostate cancer care pathway.
For more information please visit the company’s website: www.metamarkgenetics.com.
Metamark® and ProMark® are registered trademarks of Metamark Genetics, Inc.
Company Contact:
Jerry Williamson
SVP & Chief Commercial Officer
617-583-1450
Media Contact:
Toral Patel
Feinstein Kean Healthcare
732-590-3859
Help employers find you! Check out all the jobs and post your resume.
November 2, 2015
CAMBRIDGE, Mass. -- Metamark Genetics, Inc., (“Metamark” or the “Company”), a leader in commercializing high-value urologic oncology products, announced that Tyler Aldredge joined Metamark’s executive team as senior vice president of clinical laboratory operations, effective October 26, 2015.
“Tyler brings an impressive breadth of leadership experience in clinical and laboratory operations,” said Kenneth Weg, Metamark President and CEO. “We’re very excited to have someone with Tyler’s respectable background, proven management expertise, and passion for innovation in cutting-edge laboratory R&D join our team. With Tyler on board, Metamark is well-poised to serve the comprehensive diagnostic and prognostic needs of the urological clinical community with advanced testing products, including our lead product, ProMark®, which continues to make giant strides in providing better information to aid in prostate cancer treatment decisions.”
Tyler Aldredge joins the Metamark team with a wealth of leadership, operations management, and operational quality experience in both clinical and research laboratories, while bringing extensive proficiency in process development and laboratory automation. Most recently, Tyler held the position of senior director of laboratory operations at Good Start Genetics, where he directed the clinical laboratory that performs molecular genetic testing for carrier screening and pre-implantation screening. Previously, Tyler held the role of vice president of laboratory operations at Expression Analysis where he led laboratory operations for the genomic services business that provided next-gen sequencing (NGS) and microarray-based genotyping and gene expression services. Tyler has held executive and leadership positions at Quintiles Transnational, Genzyme Genetics, The Broad Institute, Harvard University's Bauer Center for Genomic Research, and Codon Devices. In the early part of his career, Tyler built high-throughput automated DNA sequencing systems for Sanofi and Genome Therapeutics, which ultimately contributed to the Human Genome Project.
Tyler received a B.S. in Bioengineering from Syracuse University and a master’s in Biomedical Engineering from the Worcester Polytechnic Institute.
About ProMark®
Launched in late 2014, ProMark® is the first proteomic classifier of biopsied prostate tissue to assess whether an early-stage prostate tumor is aggressive or indolent. Test results generated in Metamark’s Cambridge, Mass. CLIA-certified laboratory can aid the decision to treat the cancer aggressively or to choose a course of active surveillance.
About Metamark®
Metamark Genetics, Inc. is a privately-held biotechnology company founded to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care. The company’s proprietary genomic and proteomic discovery platforms have led to significant discoveries in several disease areas, including prostate, bladder, colon, and breast cancers. Through the acquisition of HealthTronics Laboratory Solutions in 2013, Metamark has become a leading provider of specialty urological pathology testing services with the first fully integrated clinical model for the prostate cancer care pathway.
For more information please visit the company’s website: www.metamarkgenetics.com.
Metamark® and ProMark® are registered trademarks of Metamark Genetics, Inc.
Company Contact:
Jerry Williamson
SVP & Chief Commercial Officer
617-583-1450
Media Contact:
Toral Patel
Feinstein Kean Healthcare
732-590-3859
Help employers find you! Check out all the jobs and post your resume.